2026-09-20T19:25:45Zhttps://wakespace.lib.wfu.edu/server/oai/requestoai:null:10339/863472026-09-02T14:09:09Zcom_10339_14934col_10339_38132
Guan, Meijian
2017-08-22T08:35:25Z
2019-08-21T08:30:13Z
2017
https://wakespace.lib.wfu.edu/handle/10339/86347
End-stage kidney disease (ESKD) is a significant public health problem in the U.S., disproportionately affecting African Americans (AAs; 1,003 per million/year) at 3.3-fold higher incidence rate than European Americans (301 per million/year), and 2-fold higher than Native Americans (499 per million/year) in 2014. Diabetic kidney disease (DKD), primarily attributed to type 2 diabetes (T2D), including ESKD and advanced chronic kidney disease (CKD) accounts for over 40% of all ESKD cases. Observation of familial aggregation in epidemiologic studies suggests that genetic factors may contribute to the risk of DKD. While apolipoprotein L1 gene (APOL1) G1 and G2 alleles explain approximately 70% of the disparity in non-diabetic ESKD in AAs, they fail to account for the excess risk of T2D-ESKD in AAs. Genetic studies have revealed >70 genome-wide significant of genetic determinants with impact on kidney diseases or kidney functions. Despite the progress, the proportion of T2D-ESKD susceptibility attributed by these kidney related genes is still unclear. The goal of this series of studies is to provide a comprehensive evaluation of the genetic architecture of T2D-ESKD in AAs.
en
Wake Forest University
African Americans
diabetes
end-stage kidney disease
genetics
statistics
Evaluation of genetic variants for Type 2 diabetes associated kidney disease in African Americans
Dissertation
Ng, Maggie
Freedman, Barry I
Bowden, Donald W
Howard, Timothy
Hsu, Fang-Chi
Ng, Maggie
Physiology and Pharmacology
2019-08-21
open.access